Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial
Merck, known as MSD outside of the United States and Canada, announced today safety and efficacy results from the open-label phase 1 KANDLELIT-001 study, a clinical trial evaluating MK-1084, an investigational next-generation KRAS G12C inhibitor, alone and …